GRCE - יחס חוב להיוון בספרים gracetx.com

Grace Therapeutics, Inc. (GRCE) is focused on the long-term expansion of its portfolio of treatments for rare neuropathologies. This narrow specialization creates binary risks, which are mitigated by the uniqueness of its developments. Demand for such drugs remains stable and independent of economic conditions. The company's debt relative to its book capitalization demonstrates financial leverage, where 0.00 determines the current value of this metric.

This indicator captures critical levels of corporate leverage relative to equity. The formula determines the share of total liabilities within the balance sheet asset structure to assess financial stability. By analyzing the debt-to-capitalization profile of the firm, an investor can identify default risks or the inefficient use of resources. A decrease in this ratio minimizes payment risks, which is critically important for Grace Therapeutics, Inc. (GRCE) prior to the commercialization of its rare CNS disease therapies.